25 years of aripiprazole: Emergence, evolution & reappraisal
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Aripiprazole, introduced 25 years ago, represents a major shift in antipsychotic pharmacotherapy through its pioneering mechanism of dopamine D₂ partial agonism. Unlike traditional first- and second-generation antipsychotics that rely primarily on D₂ antagonism, aripiprazole functions as a dopamine–serotonin stabilizer, modulating neurotransmission in both hyper- and hypodopaminergic states. This mechanism—supported by functional selectivity at D₂ and 5-HT receptors—provides effective control of positive, negative, and mood symptoms while reducing the risks of extrapyramidal symptoms, prolactin elevation, and metabolic disturbances. Over its clinical lifespan, aripiprazole has demonstrated broad efficacy as monotherapy for schizophrenia, bipolar I disorder, irritability associated with autism spectrum disorder, and Tourette’s disorder. Its versatility extends beyond monotherapy, with strong evidence for reversing antipsychotic-induced hyperprolactinaemia, augmenting clozapine in treatment-resistant schizophrenia, enhancing the effects of mood stabilizers in bipolar disorder, and serving as a robust augmentation strategy in treatment-resistant depression. Adjunctive use also shows potential for mitigating olanzapine-associated metabolic effects. Long-acting injectable formulations further support adherence and relapse prevention. After 25 years, aripiprazole remains a uniquely adaptable therapeutic option, exemplifying the clinical advantages of receptor modulation over antagonism and continuing to influence the evolution of next-generation antipsychotic development.
Fields of Study & Subjects
Schizophrenia research and treatment
Neurotransmitter Receptor Influence on Behavior
Treatment of Major Depression
Publication details
- Journal / source
- International Journal of Pharmacology and Clinical Research
- Volume
- 8
- Issue
- 3
- Pages
- 149–152
- Publication date
- 1 March 2026
- Language
- EN